Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes

Obesity Surgery

Volumn 23, Issue 9, 2013, Pages 1354-1360

  De Jonge, Charlotte ^a,b   Rensen, Sander S ^a   Verdam, Froukje J ^a   Vincent, Royce P ^c   Bloom, Steve R ^d   Buurman, Wim A ^a   Le Roux, Carel W ^d   Schaper, Nicolaas C ^a   Bouvy, Nicole D ^a   Greve, Jan Willem M ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

GIP; GLP 1; Glucagon; Gut hormones; Obesity; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; BARIATRIC SURGERY; BODY WEIGHT; CLINICAL ARTICLE; DIGESTIVE SURGICAL EQUIPMENT; DUODENAL JEJUNAL BYPASS LINER; ENDOSCOPIC SURGERY; FEMALE; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPLANTATION; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PILOT STUDY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BARIATRIC SURGERY; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DUODENUM; EATING; ENDOSCOPY; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; JEJUNUM; MALE; MIDDLE AGED; NETHERLANDS; OBESITY; PILOT PROJECTS; POSTPRANDIAL PERIOD; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84881138108     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-0921-3     Document Type: Article

References (34)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-7. (Pubitemid 34000780)
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. (Pubitemid 38579764)
3. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467-84.
4. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-93. (Pubitemid 39665322)
5. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339-50.
6. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518-25.
7. Laferrere B et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011;3(80):80re2.
8. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741-9. (Pubitemid 44629948)
9. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: Involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia. 2009;52(11):2270-6.
10. Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: A review. Surg Obes Relat Dis. 2005;1(6):589-97.
11. Rao RS, Kini S. GIP and bariatric surgery. Obes Surg. 2011;21(2):244-52.
12. Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology. 2012;143:897-912. doi: 10.1053/j.gastro.2012.07.114.
13. Rodriguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55-9.
14. Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650-6.
15. Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976-82.
16. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236-43.
17. de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183-9.
18. Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012;255(6):1080-5.
19. Goldfine AB, Shoelson SE, Aguirre V. Expansion and contraction: treating diabetes with bariatric surgery. Nat Med. 2009;15(6):616-7.
20. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet. 1987;2(8571):1300-4. (Pubitemid 17156636)
21. Menge BA, Gruber L, Jorgensen SM, et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes. 2011;60(8):2160-8.
22. Klein S, Fabbrini E, Patterson BW, et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity. 2012;20(6):1266-72.
23. Geloneze B, Geloneze SR, Fiori C, et al. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg. 2009;19(8):1077-83.
24. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824-30. (Pubitemid 34233752)
25. Umeda LM, Silva EA, Carneiro G, et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21(7):896-901.
26. Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77(5):1287-93. (Pubitemid 23345484)
27. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252(6):966-71.
28. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38(4):387-95. (Pubitemid 19105727)
29. Hare KJ, Knop FK, Asmar M, et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(12):4679-87.
30. Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107(2):248-56.
31. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13 Suppl 1:89-94.
32. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316-23. (Pubitemid 351159368)
33. Buchwald H et al. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med. 2009;122(3):248-56. e5.
34. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery for diabetes: The International Diabetes Federation takes a position. J Diabetes. 2011;3(4):261-4.